Diabetes

New data presented at the Advanced Technologies & Treatments for Diabetes 2026 highlight a shift in diabetes care beyond glucose control alone. Emerging evidence supports the growing role of incretin-based therapies such as semaglutide, alongside advances in continuous glucose monitoring systems including Dexcom G7 and Freestyle Libre 3. Together, these innovations demonstrate meaningful improvements in glycemic outcomes, cardiometabolic risk, and patient behaviors, signaling a move toward more personalized, integrated approaches to diabetes management across both type 1 and type 2 diabetes.

Urinary lithogenesis processes are activated in patients with obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D). This is a relatively unfamiliar topic among endocrinologists. Beyond the epidemiological evidence accumulated over the recent years, the purpose of this paper is ...

The past century has witnessed substantial evolution in the assessment and management of type 1 diabetes (T1D), paralleling advances in our understanding of the condition and in innovation in technology. Since the ground-breaking discovery of insulin in the 1920s, T1...

The European Association for the Study of Diabetes (EASD) Early Career Academy (ECA) has rapidly become a central initiative supporting the professional development of emerging clinicians and researchers in diabetology. Established to foster mentorship, collaboration and career progression, the Academy ...

Insulin resistance (IR), a hallmark of various metabolic disorders, represents a diminished responsiveness of target tissues to the actions of insulin, resulting in impaired glucose uptake, dyslipidaemia and endothelial dysfunction.1,2 Worldwide, the prevalence of IR among adults ranges from 15.5% to 46.5%.3–5 ...

Drawing on the experience of expert faculty and emerging leaders who have already navigated many of the early hurdles when embarking on a career in endocrinology, we asked for one piece of career advice to share with those just starting out. Their reflections highlight the importance of curiosity, compassion, adaptability and purpose in building a fulfilling and sustainable career.

There is no doubt that artificial intelligence was one of the fastest-moving technologies of 2025. Advances in predictive analytics, pattern recognition across large datasets, and the integration of genomic, phenotypic and real-world data are already beginning to reshape how clinicians diagnose disease, stratify risk and personalise care. We asked some of the experts that have collaborated with touchENDOCRINOLOGY what excites them most about AI and how they see it influencing clinical practice.

In this roundup, members of the touchNDOCRINOLOGY Expert Faculty share their perspectives on the advances that shaped research and practice over the past year, highlighting a discipline in transition and looking ahead to the opportunities of 2026.

GLP-1 receptor agonists have been a standout development this year, reshaping the treatment of type 2 diabetes and obesity. In this expert perspective, Glenn D Braunstein highlights their expanding benefits, from weight loss and cardiometabolic protection to emerging dual- and tri-agonist therapies, while also addressing key challenges as these agents move rapidly into mainstream clinical practice.